BIONDVAX PHARMA/S (NASDAQ: BVXV) is one of 107 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its peers? We will compare BIONDVAX PHARMA/S to similar businesses based on the strength of its dividends, institutional ownership, analyst recommendations, valuation, earnings, risk and profitability.
This is a summary of current ratings for BIONDVAX PHARMA/S and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|BIONDVAX PHARMA/S Competitors||651||2247||5424||220||2.61|
Valuation & Earnings
This table compares BIONDVAX PHARMA/S and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|BIONDVAX PHARMA/S||N/A||-$9.96 million||-2.90|
|BIONDVAX PHARMA/S Competitors||$1.02 billion||$93.10 million||-4.43|
BIONDVAX PHARMA/S’s peers have higher revenue and earnings than BIONDVAX PHARMA/S. BIONDVAX PHARMA/S is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This table compares BIONDVAX PHARMA/S and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|BIONDVAX PHARMA/S Competitors||-5,089.26%||-80.35%||-25.50%|
Institutional and Insider Ownership
7.0% of BIONDVAX PHARMA/S shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 6.0% of BIONDVAX PHARMA/S shares are owned by company insiders. Comparatively, 16.3% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Risk and Volatility
BIONDVAX PHARMA/S has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, BIONDVAX PHARMA/S’s peers have a beta of 1.64, suggesting that their average share price is 64% more volatile than the S&P 500.
BIONDVAX PHARMA/S peers beat BIONDVAX PHARMA/S on 8 of the 10 factors compared.
BIONDVAX PHARMA/S Company Profile
BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which has completed Phase II clinical trials that is used for treating seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Ness Ziona, Israel.
Receive News & Ratings for BIONDVAX PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIONDVAX PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.